EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial

Juan Wang iD, Wei Wang, Guanghui Xu, Shushang Liu, Longxing Jiao, Shu Wang, Chaosheng Peng, Yuxuan Ma, Xin Liu, Huade Huo, Haolin Li, Xiaohua Li und 1 weitere

MedComm · 2026-11 · 7 (11)

DOI: 10.1002/mco2.70958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 03.11.2026. Verfasst von Juan Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Surgery Xijing Hospital of Digestive Diseases Fourth Military Medical University Xi'an China. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This single‐center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) therapy or nab‐paclitaxel, lobaplatin, and S‐1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single‐center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity. Trial Registration ClinicalTrials.gov: NCT06169410

Schlagwörter

Stichwörter der Autor:innen

S‐1conversion therapylobaplatinnab‐paclitaxelramucirumabunresectable advanced gastric cancer

Autor:innen und Institutionen

  • Department of Digestive Surgery Xijing Hospital of Digestive Diseases Fourth Military Medical University Xi'an China.
  • Department of General Surgery Yulin Hospital Affiliated to the First Affiliated Hospital of Xi'an Jiaotong University Yulin China.
  • Department of Pharmaceutics and Pharmacy Administration School of Pharmacy Air Force Medical University Xi'an Xi'an China.
  • Xi'an Medical University Xi'an China.

ORCID-Profile: Juan Wang

Zitieren

APA

Wang, J., Wang, W., Xu, G., Liu, S., Jiao, L., Wang, S., Peng, C., Ma, Y., Liu, X., Huo, H., Li, H., Li, X., & Yang, J. (2026). Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial. MedComm, 7(11). https://doi.org/10.1002/mco2.70958

Vancouver

Wang J, Wang W, Xu G, Liu S, Jiao L, Wang S, et al. Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial. MedComm. 2026;7(11). doi:10.1002/mco2.70958

BibTeX
@article{Wang2026,
  author = {Wang, Juan and Wang, Wei and Xu, Guanghui and Liu, Shushang and Jiao, Longxing and Wang, Shu and Peng, Chaosheng and Ma, Yuxuan and Liu, Xin and Huo, Huade and Li, Haolin and Li, Xiaohua and Yang, Jianjun},
  title = {Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {11},
  doi = {10.1002/mco2.70958}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche